Holen Sie sich die Stockscreener-App
19.67
6.41%
1.1701
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Morningstar
Momentum Shift: Will Ultragenyx Pharmaceutical Inc outperform tech stocksGold Moves & Free Community Supported Trade Ideas - baoquankhu1.vn
Why Ultragenyx (RARE) Is Down 14.4% After Positive Phase 3 DTX301 Gene Therapy Results - simplywall.st
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Goldman Sachs Downgrades Ultragenyx (RARE), Slashes Price Target by 59% | RARE Stock News - GuruFocus
Goldman Sachs Downgrades Ultragenyx (RARE) Following Trial Setba - GuruFocus
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - Seeking Alpha
Ultragenyx stock hits 52-week low at 18.36 USD - Investing.com
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral By Investing.com - Investing.com Australia
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by The Goldman Sachs Group - MarketBeat
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire Inc.
Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61 - marketscreener.com
Goldman Sachs downgrades Ultragenyx Pharma stock rating to neutral - Investing.com UK
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Alert: Deadline in Lawsuit on April 6, 2026 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
RARE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
WOODSTOCK CORP's Ultragenyx Pharmaceutical Inc(RARE) Holding History - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire
2026-03-22 | RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:RARE | Press Release - Stockhouse
Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After A 47% One-Year Share Price Fall - Sahm
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - Sahm
How Ultragenyx Pharmaceutical Inc. (RARE) Affects Rotational Strategy Timing - Stock Traders Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new Ultragenyx hires get 10,839 stock units under Nasdaq rule - Stock Titan
A Look At Ultragenyx Pharmaceutical’s Valuation After Recent Share Price Weakness - Yahoo Finance
Mucopolysaccharidosis Treatment Market to Reach US$6.76 - openPR.com
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - Lelezard
Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
RARE DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION (2026-03-18) - Seeking Alpha
LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION - Sahm
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire
DTX301 Gene Therapy Lowers Ammonia Levels in Ornithine Transcarbamylase Deficiency at 36 Weeks - Neurology Live
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - PR Newswire
Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Phase 3 DTX301 Gene Therapy Data Could Be A Game Changer For Ultragenyx Pharmaceutical (RARE) - Sahm
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
ULTRAGENYX PHARMACEUTICAL INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Securities Fraud Lawsuit - marketscreener.com
Farallon Capital Management LLC Decreases Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
First Light Asset Management LLC Trims Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Algert Global LLC Purchases 205,286 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Rosen Law Firm Encourages Ultragenyx Investors to Secure Counsel Before Deadline - National Today
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. ... - Caledonian Record
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire
RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 (2026-03-15) - Seeking Alpha
Braidwell LP Acquires New Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):